Antibacterial activity and mechanisms of D-3263 against Staphylococcus aureus

Area of Science:

• Microbiology
• Pharmacology
• Biochemistry

Background:

• Multi-drug-resistant Staphylococcus aureus (MRSA) infections pose a significant threat, driving the need for novel antibiotic agents.
• Transient receptor potential melastatin member 8 (TRPM8) agonists, like D-3263, are being explored for therapeutic potential beyond their known antineoplastic properties.

Purpose of the Study:

• To investigate the antibacterial and antibiofilm activities of D-3263 against Gram-positive bacteria, particularly Staphylococcus aureus.
• To elucidate the mechanism of action of D-3263, focusing on its effects on bacterial cell membranes and protein expression.

Main Methods:

• Determined Minimum Inhibitory Concentrations (MICs) and Minimum Bactericidal Concentrations (MBCs) for D-3263 against S. aureus, Enterococcus faecalis, and E. faecium.
• Assessed D-3263's efficacy in inhibiting and eradicating S. aureus and E. faecalis biofilms.
• Conducted proteomic analysis to identify proteins differentially expressed under D-3263 treatment.
• Investigated the impact of D-3263 on bacterial membrane permeability and the role of specific phospholipids.

Main Results:

• D-3263 demonstrated significant antibacterial activity with MICs ≤ 50 µM against S. aureus, E. faecalis, and E. faecium.
• Bactericidal effects were observed against MRSA and E. faecalis at 4× MIC, and subinhibitory concentrations effectively inhibited biofilm formation.
• Proteomic analysis revealed alterations in amino acid biosynthesis and carbohydrate metabolism pathways.
• D-3263 increased membrane permeability and its efficacy was modulated by bacterial membrane phospholipids (PE, PG, CL).

Conclusions:

• D-3263 exhibits potent antibacterial and antibiofilm properties against Staphylococcus aureus and other Gram-positive bacteria.
• The compound's mechanism involves targeting the bacterial cell membrane, leading to increased permeability.
• D-3263 represents a promising candidate for developing new therapies against drug-resistant bacterial infections.